
UCB releases ‘Epilepsy In Our Time’ video diaries
pharmafile | February 17, 2012 | News story | Medical Communications | UCB, epilepsy
UCB has released Epilepsy In Our Time, a video diary that explores life with epilepsy from the perspective of those living with the condition.
The disease is the most common serious brain disorder in the world, affecting around six million people in Europe.
UCB has several established epilepsy drugs in a number of markets, which includes its patented medicines Keppra and Vimpat.
The Epilepsy In Our Time diaries began in 2010, and films people living with epilepsy each year to see how their daily lives have changed, and whether their hopes or ambitions have been realised.
Marion, Lloyd, Monica, Jérôme, David and Julie are six epilepsy patients who share their thoughts on the condition on a dedicated YouTube channel.
Marion Clignet, who has won two silver Olympic medals and has lived more than half her life with epilepsy, said: “There are a lot of issues and a lot of questions on people’s minds, but having epilepsy does not make you a burden to society and on the contrary it can sometimes make you even stronger.”
Lode Dewulf, VP of global medical affairs at UCB, said: “Epilepsy In Our Time provides a direct insight into what it means to live with epilepsy in 2012.
“It is important for people with epilepsy and those who care for them to connect with each other for support and inspiration. By sharing personal stories we hope to improve the perception and understanding of the condition.”
Ben Adams
Related Content

EpilepsyGTx raises $33m for focal refractory epilepsy gene therapy
EpilepsyGTx, a biotechnology company researching and developing gene therapies for the treatment of refractory epilepsy, …

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …





